Reynald Castañeda

With Lon­za an­tic­i­pat­ing per­sis­tent in­crease in de­mand for com­mer­cial bi­o­log­ics man­u­fac­tur­ing, the Swiss com­pa­ny is pick­ing up a pro­duc­tion site owned by Roche’s Genen­tech for

Spruce Bio­sciences’ tildac­er­font failed a Phase IIb test in adults with con­gen­i­tal adren­al hy­per­pla­sia (CAH) due to com­pli­ance is­sues, crush­ing its stock $SPRB by as

Af­ter years of try­ing to ex­pand the mar­ket ter­ri­to­ry for Nu­plazid, Aca­dia Phar­ma­ceu­ti­cals might have hit a dead end, with a Phase III fail­ure in

No­vo Nordisk spelled out how it will try to catch up with the ex­tra­or­di­nary de­mand for its GLP-1 drugs, un­der­scor­ing its ra­tio­nale for its in-house

Mod­er­na has made cuts at its Burling­ton and Nor­wood sites in Mass­a­chu­setts, a spokesper­son con­firmed to End­points News, in­clud­ing some work­ers in qual­i­ty as­sur­ance. “Mod­er­na pre­vi­ous­ly

Boehringer In­gel­heim said on Mon­day that its “dou­ble G” meta­bol­ic dys­func­tion-as­so­ci­at­ed steato­hep­ati­tis (MASH) drug de­liv­ered pos­i­tive topline re­sults in a Phase II tri­al. The com­pa­ny

Plus, Oc­u­lar Ther­a­peu­tix’s pri­vate place­ment, Lim­maT­e­ch Bi­o­log­ics’ shigel­losis vac­cine da­ta and a col­lab­o­ra­tion be­tween Hox Ther­a­peu­tics and Ver­nalis. MD An­der­son buys tech from Bel­licum: The Texas

GSK is look­ing to ride the mo­men­tum from its RSV vac­cine sales in­to 2024 and be­yond. Mean­while, it has cut three in­fec­tious dis­ease can­di­dates from

Ab­b­Vie is not on­ly build­ing out its pipeline, but al­so its man­u­fac­tur­ing foot­print. The Chica­go-based phar­ma is spend­ing $223 mil­lion to ex­tend its on­ly man­u­fac­tur­ing

A for­mer Pfiz­er em­ploy­ee was found guilty of buy­ing stock op­tions a day be­fore the com­pa­ny un­veiled pos­i­tive Covid-19 drug da­ta. Amit Da­gar was a